相关实验视频

Updated: Jul 4, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

降脂药物与大动脉动脉瘤的遗传关联:孟德尔的随机化研究

Xiong Gao¹, Wei Luo¹, Liyuan Qu²

¹Department of Cardiovascular Medicine, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Baiyun District, Guangzhou City, Guangdong Province 510515, China.

European journal of preventive cardiology

|February 1, 2024

概括

这项研究调查了降脂药物和大动脉动脉瘤 (AA) 之间的遗传联系. 较高的HMGCR,PCSK9和CETP基因表达增加了AA风险,这表明了这种疾病的潜在治疗点.

科学领域:

心血管遗传学心血管遗传学
药物基因组学药物基因组学
大动脉疾病研究研究

背景情况:

大动脉动脉瘤 (AA) 缺乏有效的药物治疗方法,这构成了临床挑战.
脂质代谢与AA病原发生有关,但降脂药物的作用仍在争论中.
调查遗传关联可以澄清降脂干预措施与AA风险之间的关系.

研究的目的:

通过遗传学研究降脂药物与大动脉动脉瘤风险和进展之间的关联.
确定影响脂质修饰药物标的遗传变异是否因果影响AA.
探索特定的脂质调节基因表达对大动脉尺寸的影响.

主要方法:

利用公开可用的全基因组关联研究 (GWAS) 和表达量化特征位点 (eQTL) 数据.
采用药物标孟德尔随机化 (MR),使用药物标基因的eQTL和与脂质相关的位置附近的SNP作为遗传工具.
分析了降脂药物的遗传代理和AA风险之间的关联,包括大动脉光大小.

主要成果:

增加HMGCR (3-基-3-甲基氨酸共酶A减少酶) 的表达因果相关,与较高的AA风险 (OR=1.58) 和较大的大动脉光膜大小有关.
发现PCSK9 (proprotein convertase subtilisin/kexin type 9) 和CETP (胆固醇转移蛋白) 与AA风险增加有暗示性关联.
没有重要的遗传证据将NPC1L1 (Niemann-Pick C1-Like 1) 或LDLR (低密度脂蛋白胆固醇受体) 与AA风险联系起来.

结论:

提供因果遗传证据,将降脂药物标与大动脉动脉瘤发展联系起来.
较高的HMGCR,PCSK9和CETP的基因表达被确定为AA的危险因素.
抑制HMGCR可能会降低大动脉膜的大小,这需要进一步的临床研究.

关键词:

大动脉动脉瘤是大动脉动脉瘤.因果关系是因果关系.遗传仪器是一种基因仪器.降脂药物降脂药物降脂药物门德尔的随机化

更多相关视频

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...